What exactly causes ulcerative colitis is not understood, often known as UC. However, studies have uncovered a few potential causes of the condition, which are as follows:
Immune reactions:The body's immune system launches an assault against the mucosal lining of the large intestine (an autoimmune disorder).
Environmental factors:Consumption of a diet that is rich in fat, sulfur, and the amount of meat consumed, various pharmaceuticals, abuse of alcoholic beverages and illicit drugs, stress on a person's psyche
Medications:Taking nonsteroidal anti-inflammatory medicines (NSAIDs) might increase your chance of developing ulcerative colitis (UC).
Milk:Consumption has the potential to make the condition worse.
Vidofludimus is a new oral immunomodulatory medication tested in Phase II trials for inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and preclinical trials for lupus.
Vidofludimus is a potent inhibitor of DHODH, a critical enzyme in de novo pyrimidine biosynthesis, and hence limits the proliferation of activated T and B cells by inhibiting DHODH.
Vidofludimus also inhibits the expression of pro-inflammatory cytokines such as IL-17 in activated lymphocytes, even in exogenous uridine, indicating a pharmacological effect independent of inhibiting DHODH and T-cell proliferation, but the targeting mechanism remains unknown.
Medication repositioning provides more efficiency than standard drug development by identifying their potential for functionally engaging with unexpected targets.
This method has the potential to increase the optimization of existing medications and lead to novel therapeutic switching.
Vidofludimus was discovered to be a new farnesoid X receptor modulator with therapeutic promise in the treatment of non-alcoholic fatty liver disease.
Metabolic stress from DHODH inhibition reduces pro-inflammatory cytokine production, particularly IL-17 (IL-17A and IL-17F), and increases lymphocyte death.
The study includes a blinded induction phase to determine the optimal dose of IMU-838 to induce response and remission, a blinded maintenance phase to evaluate IMU-838's ability to maintain remission until Week 50, and an open-label treatment extension arm for patients who discontinue the blinded phase as scheduled or prematurely, subject to certain restrictions.
A selection of patients will undergo pharmacokinetic (PK) testing to create a single-dose PK profile.